DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

Information source: Janssen Korea, Ltd., Korea
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer; Pain

Intervention: Hydromorphone HCl OROS (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen Korea, Ltd., Korea

Official(s) and/or principal investigator(s):
Janssen Korea, Ltd., Korea Clinical Trial, Study Director, Affiliation: Janssen Korea, Ltd., Korea

Summary

The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain after the administration of hydromorphone HCl OROS in Korean cancer participants.

Clinical Details

Official title: Cancer Pain Management With Hydromorphone HCl ORal Osmotic System in Korean Cancer Patient: Evaluation of Its Clinical Usefulness in Reduction of Breakthrough Pain Medication Frequency

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants With Dosing Frequency of Analgesics for Treating Breakthrough Pain

Secondary outcome:

Frequency of Experiencing Breakthrough Pain

Change From Baseline in Korean - Brief Pain Inventory (K-BPI) Score at Day 15

Pain Intensity Score

Global Assessment of Overall Efficacy of Study Drug by Investigator

Global Assessment of Overall Efficacy of Study Drug by Participant

Participant's Preferences Along With Reasons

Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score

European Organisation for Research and Treatment of Cancer Quality of Life (EQRTC QLQ-C30) Score

Detailed description: This is an open-label (all people know the identity of the intervention), multi-center (conducted in more than 1 center), prospective (study following participants forward in time) study. The total duration of study will be 3 weeks. The study consists of 2 periods and 4 visits: screening period (1 week; Visit 1) and treatment period (2 weeks; Visit 2, 3 and 4). During screening period at Visit 1, potential participants will receive previously administered oral opioid analgesic until the second visit and with immediate-release opioid analgesic whenever breakthrough pain is present. During treatment period, from second visit to the fourth visit, participants will receive the hydromorphone HCl OROS once daily for 2 weeks. At Investigator's discretion, participants completing 2 weeks of treatment with study drug could be enrolled into the extension phase of 12-weeks. The dose of study drug is flexible and will be increased or decreased based on the frequency of immediate-release opioid analgesic doses needed to manage pain. At second visit, initial dose of hydromorphone will be determined according to the equivalent analgesic effect conversion tablet (oxycodone 10 milligram [mg] twice daily is equal to hydromorphone HCl 8 mg once daily). The Investigator will increase a participant's daily dose if more than 3 breakthrough pain episodes require rescue medication within a 24 hours period. Participants' safety will be monitored throughout the study.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Cancer participants administering only strong oral opioid analgesic for cancer pain

control

- Participants administering short-acting narcotic analgesics at least twice daily due

to breakthrough pain for 3 days just before Visit 2 (Day 1)

- Participants sufficiently capable of complying overall study requirements including

participant diary for pain at the discretion of the Investigators

- Abstinent or surgically sterile female participants

Exclusion Criteria:

- Participants with cancer pain who are potentially unresponsive to narcotic

analgesics

- Participants with presence or history of drug or alcohol abuse within the past 6

months

- Participants with hypersensitivity to hydromorphone HCl

- Participants with history of colectomy (surgery to remove part or all of the colon)

- Participants with severe digestive tract disease which might interfere with oral

analgesic effects, such as dysphagia (trouble swallowing), vomiting, no bowel movement, ileus, and severe enterostenosis that can influence absorption and passing through of oral medication

Locations and Contacts

Additional Information

Starting date: October 2008
Last updated: July 9, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017